Costs and Factors Associated with Hospitalizations Due to Severe Influenza in Catalonia (2017-2020).
comorbidity
hospital costs
hospitalization
influenza vaccination
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
10 11 2022
10 11 2022
Historique:
received:
11
10
2022
revised:
04
11
2022
accepted:
07
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
This study aimed to estimate the cost and factors associated with severe hospitalized patients due to influenza in unvaccinated and vaccinated cases. The study had a cross-sectional design and included three influenza seasons in 16 sentinel hospitals in Catalonia, Spain. Data were collected from a surveillance system of influenza and other acute respiratory infections. Generalized linear models (GLM) were used to analyze mean costs stratified by comorbidities and pregnancy. Multivariate logistic models were used to analyze bacterial coinfection, multi-organ failure, acute respiratory distress syndrome, death and ICU admission by season and by vaccination status. Costs of ICU, hospitalization and total mean costs were analyzed using GLM, by season and by vaccination status. All models were adjusted for age and sex. A total of 2742 hospitalized cases were included in the analyses. Cases were mostly aged ≥ 60 years (70.17%), with recommended vaccination (86.14%) and unvaccinated (68.05%). The ICU admission level was statistically significant higher in unvaccinated compared to vaccinated cases. Costs of cases with more than or equal to two comorbidities (Diff = EUR - 1881.32), diabetes (Diff = EUR - 1953.21), chronic kidney disease (Diff = EUR - 2260.88), chronic cardiovascular disease (Diff = EUR - 1964.86), chronic liver disease (Diff = EUR - 3595.60), hospitalization (EUR 9419.42 vs. EUR 9055.45), and total mean costs (EUR 11,540.04 vs. 10,221.34) were statistically significant higher in unvaccinated compared to vaccinated patients. The influenza vaccine reduces the costs of hospitalization. There is a need to focus strategies in recommended vaccination groups.
Identifiants
pubmed: 36429510
pii: ijerph192214793
doi: 10.3390/ijerph192214793
pmc: PMC9690392
pii:
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
BMC Infect Dis. 2016 Jan 08;16:6
pubmed: 26743673
J Healthc Qual Res. 2022 Jul-Aug;37(4):201-207
pubmed: 35165077
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2019 Jan 11;14(1):e0210353
pubmed: 30633778
Influenza Other Respir Viruses. 2018 Jan;12(1):22-29
pubmed: 29197154
PLoS One. 2018 Sep 7;13(9):e0202787
pubmed: 30192781
Gac Sanit. 2021 Jul-Aug;35(4):339-344
pubmed: 32331814
Eur J Health Econ. 2020 Jul;21(5):775-785
pubmed: 32180069
N Engl J Med. 2007 Oct 4;357(14):1373-81
pubmed: 17914038
PLoS One. 2017 Jan 26;12(1):e0170550
pubmed: 28125629
Med Intensiva. 2009 Dec;33(9):455-8
pubmed: 19854543
PLoS One. 2015 Mar 04;10(3):e0118369
pubmed: 25738736
Int J Environ Res Public Health. 2019 Mar 01;16(5):
pubmed: 30832264
Eur J Health Econ. 2022 Feb;23(1):67-80
pubmed: 34283323